Research Article
Molecular Serotyping and Antibiotic Resistance Patterns of Escherichia coli Isolated in Hospital Catering Service in Morocco
Table 5
Antibiotic resistance profiles detected in E. coli.
| | Profile | N (%) | Food | Food contact surfaces | Hand carriage |
| 2 ATB | 1 | AMC. AMP | - | — | 2 (3.4) |
| 3 ATB | 2 | AMC. AMP. CN | — | 1 (5.6) | — | 3 | AMC. AMP. NA | — | — | 1 (1.7) | 4 | AMC. AMP. SXT | 1 (2.3) | — | — | 5 | AMC. AMP. IPM | 2 (4.7) | — | 1 (1.7) | 6 | AMC. AMP. CAZ | — | — | 4 (6.9) | 7 | AMC. AMP. CFM | — | — | 3 (5.2) |
| 4 ATB | 8 | AMC. AMP. CN. NA | 1 (2.3) | — | — | 9 | AMC. AMP. NA. IPM | 1 (2.3) | — | — | 10 | AMC. AMP. NA. CAZ | — | — | 1 (1.7) | 11 | AMC. AMP. IPM. CAZ | 1 (2.3) | — | — | 12 | AMC. AMP. IPM. CFM | — | — | 1 (1.7) | 13 | AMC. AMP. CAZ. CFM | 3 (7) | — | 3 (5.2) |
| 5 ATB | 14 | AMC. AMP. CN. SXT. NA | 1 (2.3) | — | 3 (5.2) | 15 | AMC. AMP. CN. NA. IPM | 1 (2.3) | — | — | 16 | AMC. AMP. CN. NA. CAZ | 2 (4.7) | — | — | 17 | AMC. AMP. CN. SXT. IPM | 2 (4.7) | — | 1 (1.7) | 18 | AMC. AMP. SXT. NA. IPM | — | — | 1 (1.7) | 19 | AMC. AMP. CN. SXT. CFM | 3 (7) | — | — | 20 | AMC. AMP. CN. IPM. CFM | — | — | 1 (1.7) | 21 | AMC. AMP. CN. CAZ. CFM | 2 (4.7) | — | 4 (6.9) | 22 | AMC. AMP. NA. CAZ. CFM | 1 (2.3) | — | — | 23 | AMC. AMP. NA. IPM. CFM | 1 (2.3) | — | — | 24 | AMC. AMP. SXT. NA. CFM | 2 (4.7) | — | — | 25 | AMC. AMP. IPM. CAZ. CFM | — | 1 (5.6) | 1 (1.7) |
| 6 ATB | 26 | AMC. AMP. CN. NA. CAZ. CFM | — | 1 (5.6) | — | 27 | AMC. AMP. CN. NA. IPM. CAZ | — | 1 (5.6) | 3 (5.2) | 28 | AMC. AMP. CN. NA. IPM. CFM | 1 (2.3) | — | 3 (5.2) | 29 | AMC. AMP. CN. SXT. NA. IPM | 2 (4.7) | — | 3 (5.2) | 30 | AMC. AMP. CN. SXT. NA. CAZ | 1 (2.3) | — | 1 (1.7) | 31 | AMC. AMP. CN. SXT. NA. CFM | 1 (2.3) | — | 2 (3.4) | 32 | AMC. AMP. CN. SXT. IPM. CAZ | — | — | 1 (1.7) | 33 | AMC. AMP. SXT. NA. IPM. CFM | 2 (4.7) | — | — | 34 | AMC. AMP. NA. IPM. CAZ. CFM | 2 (4.7) | — | — | 35 | AMC. AMP. CN. IPM. CAZ. CFM | 1 (2.3) | — | — | 36 | AMC. AMP. SXT. NA. CAZ. CFM | 1 (2.3) | 1 (5.6) | — | 37 | AMC. AMP. SXT. IPM. CAZ. CFM | 1 (2.3) | — | — |
| 7ATB | 38 | AMC. AMP. CN. SXT. NA. IPM. CAZ | 4 (9.3) | — | 3 (5.2) | 39 | AMC. AMP. CN. SXT. NA. IPM. CFM | 1 (2.3) | — | 1 (1.7) | 40 | AMC. AMP. CN. NA. IPM. CAZ. CFM | — | 3 (16.7) | 1 (1.7) | 41 | AMC. AMP. CN. SXT. NA. CAZ. CFM | 1 (2.3) | — | 2 (3.4) | 42 | AMC. AMP. CN. SXT. IPM. CAZ. CFM | — | — | 1 (1.7) | 43 | AMC. AMP. SXT. NA. IPM. CAZ. CFM | 1 (2.3) | 1 (5.6) | 2 (3.4) | 8 ATB | 44 | AMC. AMP. CN. SXT. NA. IPM. CAZ. CFM | — | 9 (50) | 8 (13.8) |
|
|
- : absent; AMP: ampicillin; CN: gentamicin; SXT: trimethoprim-sulfamethoxazole; NA: nalidixic acid; IPM: imipenem; CAZ: ceftazidime; and CFM: cefotaxime. |